Notice2024-04424
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
March 4, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 43 (Monday, March 4, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 43 (Monday, March 4, 2024)]
[Notices]
[Page 15596]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-04424]
[[Page 15596]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Benjamin Hurley at 240-276-5489 or
<a href="/cdn-cgi/l/email-protection#066463686c676b6f68286e73746a637f46686f6e28616970"><span class="__cf_email__" data-cfemail="afcdcac1c5cec2c6c181c7daddc3cad6efc1c6c781c8c0d9">[email protected]</span></a>. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852: tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Vaccinia Virus Strain WR With Deletion of Growth Factor Genes
(``vSC20'')
Description of Technology:
This technology relates to mutant vaccinia virus expression
vectors. Researchers at NIAID have developed a recombinant vaccinia
virus in which the growth factor genes were deleted from both ends of
the genome. The recombinant vaccinia virus is attenuated and can
replicate efficiently in rapidly dividing cells such as tumors.
The mutation in the recombinant virus was confirmed through various
tests, including Southern blot analysis and growth factor assays. The
mutant expression vectors show diminished virus replication in non-
dividing cells and attenuation in animal models compared to other
vaccinia virus expression vectors. They may have use as vaccines,
cancer therapies as well as for gene delivery.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications:
<bullet> Recombinant vaccinia virus with deletion of growth factor
genes can be used for cancer therapeutics and diagnostics.
Competitive Advantages:
<bullet> The recombinant vaccinia virus is attenuated and can
replicate efficiently in rapidly dividing cells, such as tumors.
<bullet> Applications include use in tumor-directed gene therapy,
given the enhanced safety profile, tumor selectivity, and the oncolytic
effects after systemic delivery.
Development Stage:
<bullet> Pre-Clinical.
Inventors: Bernard Moss, M.D., Ph.D. and Sekhar Chakrabarti, Ph.D.,
both of NIAID.
Publications: Buller, R M et al. ``Deletion of the vaccinia virus
growth factor gene reduces virus virulence.'' Journal of virology vol.
62,3 (1988): 866-74. doi:10.1128/JVI.62.3.866-874.1988; McCart, J A et
al. ``Systemic cancer therapy with a tumor-selective vaccinia virus
mutant lacking thymidine kinase and vaccinia growth factor genes.''
Cancer research vol. 61,24 (2001): 8751-7.
Intellectual Property: HHS Reference No. E-028-2021. U.S. Patent
8506947B2, issued on August 13, 2013.
Licensing Contact: To license this technology, please contact
Benjamin Hurley at 240-276-5489 or <a href="/cdn-cgi/l/email-protection#284a4d46424945414606405d5a444d5168464140064f475e"><span class="__cf_email__" data-cfemail="7210171c18131f1b1c5c1a07001e170b321c1b1a5c151d04">[email protected]</span></a> and
reference E-028-2021.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. For collaboration
opportunities, please contact Benjamin Hurley at 240-276-5489 or
<a href="/cdn-cgi/l/email-protection#2042454e4a414d494e0e4855524c4559604e49480e474f56"><span class="__cf_email__" data-cfemail="781a1d16121915111656100d0a141d0138161110561f170e">[email protected]</span></a>.
Dated: February 14, 2024.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-04424 Filed 3-1-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on March 4, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.